Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316145 | 1.00 | HDAC4 (0.45) | HDAC4HDAC9 | |
| SCHEMBL16112425 | 0.78 | HDAC4 (0.50) | HDAC4HDAC9 | |
| SCHEMBL16111763 | 0.77 | HDAC4 (0.56) | HDAC4 | |
| SCHEMBL16113441 | 0.76 | HDAC4 (0.45) | HDAC4HDAC9 | |
| SCHEMBL16111963 | 0.74 | HDAC4 (0.55) | HDAC4HDAC9 | |
| SCHEMBL16111979 | 0.72 | HDAC4 (0.56) | HDAC4 | |
| SCHEMBL16132806 | 0.71 | HDAC4 (0.70) | HDAC4HDAC9 | |
| SCHEMBL16111974 | 0.70 | HDAC4 (0.68) | HDAC4HDAC9 | |
| SCHEMBL17473924 | 0.69 | HDAC9 (0.52) | HDAC4HDAC9 | |
| SCHEMBL17315990 | 0.68 | HDAC9 (0.37) | HDAC4HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148539-B1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10457675-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10065948-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9783488-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170101402-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-04-13 | — | — | US | disclosed |
| US-9617259-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3148539-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | BIOFOCUS DPI LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015187542-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065948-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC6, HDAC5 | HDAC4 7/4885HDAC9 6/4885 |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC9 7/4885 |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC9 7/4885 |
| US-20160039745-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC9 7/4885 |
| US-10457675-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC2 | HDAC4 10/4885HDAC9 8/4885 |
| US-20170101402-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC6, HDAC5 | HDAC4 7/4885HDAC9 6/4885 |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | HDAC4 10/4885HDAC9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.